what factors influence choice of first therapy in ibd: how can we predict response and be smarter?
Published 7 years ago • 604 plays • Length 20:00Download video MP4
Download video MP3
Similar videos
-
21:25
first-line therapy options in ibd: understanding longitudinal severity
-
26:25
understanding non-response and loss of response in ibd: which is it and when do we change classes?
-
15:15
first line therapies for ulcerative colitis and crohn's disease
-
27:12
evaluating and treating pain in ibd
-
21:30
ibd: beyond combination therapy
-
21:36
keynote: evolution of disease management in ibd
-
26:49
update on the therapeutic drug monitoring in ibd: for use in situations other than loss of response?
-
23:09
ibd: clinical scenarios and smart treatment options
-
21:35
how to access and determine the severity and complications of small bowel crohn’s disease
-
27:04
keynote speaker: what will be the exciting clinical challenges in ibd in 2019?
-
18:23
who should receive early anti-tnf therapy: with what benefits and risks?
-
21:36
crohn's disease: recent and emerging therapies
-
30:34
advances in anti-cytokine therapy for ibd: the role of il-12/23 and il-23 inhibitors
-
20:48
defining an ibd patient's disease severity and prognosis
-
20:09
recent and emerging crohn's disease therapies
-
6:28
why do i have ibd? treatment options and research in ibd
-
21:14
when and how to use immunomodulators and biologics in ibd
-
28:12
current and evolving therapeutic landscape of ibd
-
21:36
how will future therapeutic pathways change for ulcerative colitis and crohn's disease?